Welcome to our dedicated page for Onconetix news (Ticker: BWV), a resource for investors and traders seeking the latest updates and insights on Onconetix stock.
Onconetix, Inc. (Nasdaq: ONCO) is a commercial stage biotechnology company specializing in the research, development, and commercialization of proprietary therapeutics, diagnostics, and services for oncology. Originally known as Blue Water Biotech, Inc. (BWV), the company underwent a transformation with its recent acquisition of Proteomedix AG, a commercial-stage diagnostics oncology firm from Switzerland. This strategic move reflects Onconetix's commitment to addressing significant unmet medical needs in the field of cancer treatment and diagnostics.
Products and Innovations:
- ENTADFI®: An FDA-approved, once-daily oral therapeutic for the treatment of benign prostatic hyperplasia (BPH). This treatment combines finasteride, a 5α-reductase inhibitor, and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor, offering a more effective solution compared to other available therapies. Clinical trials have shown that ENTADFI® is more effective in alleviating BPH symptoms with fewer adverse sexual side effects.
- Proclarix®: A CE-certified diagnostic tool for prostate cancer, available in Europe and expected to launch in the U.S. in 2024. It uses a risk score combining in-vitro assays and a proprietary algorithm to evaluate the risk of clinically significant prostate cancer based on specific biomarkers found in blood serum.
Strategic Shifts and Achievements:
Onconetix's rebranding and strategic acquisition of Proteomedix have positioned the company at the forefront of prostate cancer diagnostics and treatment. By integrating Proteomedix’s advanced diagnostic technologies, Onconetix aims to enhance its global footprint and solidify its commercial portfolio in oncology. Additionally, the company has shifted focus from its preclinical vaccine programs to concentrate on more targeted oncology initiatives.
Under the leadership of Dr. Neil J. Campbell, President and CEO, Onconetix continues to build key partnerships and acquire vital assets in the oncology space. This approach ensures the company’s commitment to delivering innovative solutions to clinicians, patients, and caregivers, while enhancing shareholder value.
For more information about Onconetix, Inc., visit www.onconetix.com.
Blue Water Vaccines (BWV) announced its participation in the Biotech Showcase 2023 on January 11, 2023, during the J.P. Morgan Healthcare Conference in San Francisco. Management will present an overview of the company, discuss recent milestones, and provide updates on their vaccine pipeline. Joseph Hernandez, CEO, highlighted their progress in advancing vaccines for global health challenges. The session is set for 2:30 p.m. PST at Hilton San Francisco Union Square. Attendees can arrange one-on-one meetings with BWV management via the provided contact information.
Blue Water Vaccines (BWV) announced its first analyst coverage since going public in February 2022, receiving 'buy' ratings from Maxim Group LLC and H.C. Wainwright at price targets of $4 and $7 respectively. The company, focused on developing vaccines for global health challenges, expressed confidence that these recommendations reflect its transformative vaccine programs. Joseph Hernandez, BWV's CEO, noted the company feels undervalued and aims to show its true value as it advances towards clinical trials. The press release includes disclaimers regarding the analysts' compensation and forward-looking statements.
Blue Water Vaccines (BWV) will host an online Key Opinion Leader (KOL) event on December 7, 2022, featuring insights on vaccines that promote mucosal immunity, including the urgent need for an intranasal pneumococcal vaccine. Key presentations will be made by CEO Joseph Hernandez, Dr. Ali Fattom, and Dr. Jason Rosch, focusing on the development of BWV-201, a novel pneumococcal vaccine. The event will also cover project milestones leading to Phase I clinical trials.
Blue Water Vaccines (BWV) announced that Ali Fattom, Ph.D., will present at the World Vaccine & Immunotherapy Congress in San Diego on December 1, 2022. The presentation will focus on BWV-201, an intranasally delivered vaccine candidate targeting Streptococcus pneumoniae for preventing acute otitis media (AOM) and pneumococcal pneumonia. CEO Joseph Hernandez expressed excitement about the program's progress, which may also protect against invasive pneumococcal disease. BWV is developing transformational vaccines to tackle significant global health challenges.
Blue Water Vaccines (BWV) announced Q3 2022 results with a net loss of approximately $3.9 million, increasing from $1.1 million in Q3 2021. The company reported cash reserves of $29.1 million as of September 30, 2022, sufficient to fund operations into Q3 2024. BWV is advancing its vaccine candidates, including BWV-201 for pneumococcal pneumonia. Notable developments include a share repurchase program authorized for up to 5 million shares and promising data indicating protective efficacy against pneumonia in preclinical studies.
Blue Water Vaccines (BWV) recently appointed Vuk Jeremić to its board of directors. Jeremić, with extensive experience in operational and global strategy advisement, previously served as Serbia's Minister of Foreign Affairs and President of the UN General Assembly. His roles at a public policy think-tank and advisory positions in private equity and cryptocurrency enhance BWV's strategic direction. The CEO expressed confidence in Jeremić's ability to provide fresh insights as BWV advances its vaccine candidates, including a universal flu vaccine and treatments for norovirus and pneumonia.
Blue Water Vaccines (BWV) announced plans to evaluate its vaccine candidate, BWV-201, designed for preventing Streptococcus pneumoniae infections, at the World Vaccine Congress in Barcelona. Recent studies indicate that BWV-201 may also protect against non-invasive pneumococcal pneumonia, an area of significant unmet medical need. Traditional vaccines have limited efficacy against this condition, while BWV-201 aims to induce a robust mucosal immune response. The CDC estimates that non-invasive pneumococcal pneumonia causes about 150,000 U.S. hospitalizations annually, especially affecting older adults.
Blue Water Vaccines Inc. (BWV) will host a roundtable discussion and present at the World Vaccine Congress Europe 2022 in Barcelona on October 12-13, 2022. The event will focus on mathematical modeling for vaccine development, moderated by Dr. Sunetra Gupta from the University of Oxford. Dr. Gupta will also discuss BWV's universal influenza vaccine candidate, BWV-101. Additionally, Dr. Brian Price will present on BWV-201, a vaccine for acute otitis media in children. BWV management will be available for one-on-one meetings during the conference.
Blue Water Vaccines Inc. (BWV), a biopharmaceutical company focused on innovative vaccines, announced an update on its presence at the H.C. Wainwright 24th Annual Global Investment Conference. Joseph Hernandez, BWV's CEO, will present on September 12, 2022, at 9 AM EDT in New York City. This presentation will also be available via webcast. The company aims to address global health challenges with vaccines targeting diseases like the flu and norovirus. Interested investors can schedule one-on-one meetings with BWV management during the conference.
Blue Water Vaccines (BWV) has announced that its Chairman and CEO, Joseph Hernandez, will present at H.C. Wainwright's 24th Annual Global Investment Conference from September 12-14, 2022, in New York. The presentation will be available on-demand starting September 12 at 7:00 AM EST. BWV is focused on developing innovative vaccines for global health issues, including a universal flu vaccine and candidates for norovirus and pneumonia. Management will also be available for one-on-one meetings during the conference.
FAQ
What is the market cap of Onconetix (BWV)?
What is Onconetix, Inc.?
What products does Onconetix offer?
What is ENTADFI®?
What is Proclarix®?
What is the significance of the Proteomedix acquisition?
What are the future plans for Onconetix?
Who is leading Onconetix?
Are there any changes in Onconetix's business strategy?
Where is Onconetix headquartered?
How can I get more information about Onconetix?
